3,167 reports of this reaction
13.6% of all DURVALUMAB reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 3,167 FDA adverse event reports linking DURVALUMAB to DEATH. This represents approximately 13.6% of all 23,251 adverse event reports for this drug.
Patients taking DURVALUMAB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a frequently reported adverse event for DURVALUMAB, accounting for a significant proportion of all reports.
In addition to death, the following adverse reactions have been reported for DURVALUMAB:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 3,167 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 13.6% of all adverse event reports for DURVALUMAB, making it one of the most commonly reported side effect.
If you experience death while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.